Products for Research Use Only

LASSBio-1135

CAT: 0804-HY-131986-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-131986-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
LASSBio-1135 (Compound 3a) is an orally active TRPV1 antagonist. LASSBio-1135 is an anti-inflammatory and analgesic compound. LASSBio-1135 inhibits moderately the human PGHS-2 enzyme activity (IC50 = 18.5 μM). LASSBio-1135 reverts the Capsaicin -induced thermal hyperalgesia and reduces the carrageenan-induced rat paw edem[1].
CAS Number
852453-71-5
UNSPSC
12352005
Target
TRP Channel
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel; Neuronal Signaling
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/lassbio-1135.html
Purity
99.05
Solubility
DMSO : 6.67 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
C12=NC(C3=NC=CC=C3)=C(NC4=CC=CC=C4)N1C=CC=C2
Molecular Formula
C18H14N4
Molecular Weight
286.33
References & Citations
[1]Lacerda RB, et al. Discovery of novel analgesic and anti-inflammatory 3-arylamine-imidazo[1,2-a]pyridine symbiotic prototypes. Bioorg Med Chem. 2009 Jan 1;17 (1) :74-84.|[2]Lima CK, et al. LASSBio-1135: a dual TRPV1 antagonist and anti-TNF-alpha compound orally effective in models of inflammatory and neuropathic pain. PLoS One. 2014 Jun 18;9 (6) :e99510.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported